Alphabet, Eli Lilly, Dong-A ST and Alexandria Real Estate Equities backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.
Sonoma Biotherapeutics, a US-headquartered immunotherapy developer, has raised $265m in a series B round featuring corporates Alphabet, Eli Lilly, Dong-A ST and Alexandria Real Estate Equities.
The round was led by private equity firm Ally Bridge Group and backed by investment and financial services group Fidelity Management & Research Company.
They were joined by Osage University Partners, ArrowMark Partners, Avidity Partners, Casdin Capital, Deep Track Capital, Frazier Healthcare Partners, Janus Henderson Investors, Mirae Asset, Piper Heartland Healthcare Capital, Vertex Ventures…
